Top Nav

Michael Castor: The Accounting Game

Chris Preston

Michael Castor of Sio Capital is up next.

Castor talked about a Mexican small-cap stock called Genomma Lab (LABB.MX). Genomma is a healthcare company that trades in Mexico and has a valuation of $30 billion pesos, or $2.3 billion U.S. dollars.

There are several things to like about Genomma: It has healthy operating margins – 25%-plus – for the past five years. Net income of 5.2 billion pesos.

Genomma is similar to U.S. companies Unilever (NYSE: UN) and Colgate-Palmolive (NYSE: CL). It has a diverse array of healthcare products.

Revenues are growing – 1.8 billion pesos per year the last five years. Working capital is also increasing.

However, and this is the catch: cash flow is decreasing – mostly due to accounting irregularities. Cash flow from operations was only 1.8 billion pesos last year. The discrepancy between Genomma’s revenue and net income growth and its cash flow decline is an accounting anomaly that, Castor says, may require the company to restate earnings.

And it's why Castor is short-selling Genomma.

Income and Prosperity Offer

Income & Prosperity is designed to help you seek out the safest income opportunities and discover an entire world of dividend investments. This free newsletter has a laser-like focus on one issue and one issue only: how can investors near or in retirement generate more income. Each day, you'll receive our best investment idea - skewed towards safe income - but also including lesser known opportunities to grow your wealth while keeping it out of harm's way.
You've successfully subscribed, click the link in your email to confirm your subscription.
There was an error, and you have not been subscribed, please try again.